Home » Newsletters » BioWorld Science

BioWorld Science

July 12, 2018

View Archived Issues

Exosomes deliver no-NO arginase in diabetes

Novel TZD CMHX-008 maintains insulin sensitization with minor effects on weight gain and bone loss

Feeding findings may hold key to appetite control

Achillion initiates first-in-human study of ACH-5548

Researchers develop a rat model of diabetic cardiomyopathy for cardiovascular evaluation

FDA clears IND for Adagene's phase I study of ADG-106

Investigating isoflavonoids for the potential treatment of obesity and diabetes

[225Ac]DOTA-PEG7-5B1 as pretargeted radioimmunotherapy for pancreatic ductal adenocarcinoma

BioSight receives clearance to initiate phase IIb study of BST-236 in AML

Ovid Therapeutics initiates phase II ROCKET trial of OV-101 in fragile X syndrome

Tegsedi approved in the E.U. for the treatment of hATTR

First patient dosed in phase II study of CV-301 plus nivolumab in metastatic colorectal cancer

Recursion set to begin phase I study of AI/ML-based drug candidate, REC-994

Advaxis withdraws conditional MAA for axalimogene filolisbac, advances ADXS-HOT program

Argenx presents phase II data for ARGX-113 in myasthenia gravis

OG-716, a lantibiotic that is active against Clostridium difficile infections

Amgen describes new beta-secretase inhibitors

National Center for Global Health and Medicine, Kumamoto University and Yamasa patent antivirals

Galapagos, AbbVie discover CFTR modulators

Pivotal study of KP-415 in children with ADHD meets primary efficacy endpoint

New phase II trial explores voclosporin ophthalmic solution for dry eye syndrome

Genmab and Immatics partner on next-generation bispecific cancer immunotherapies

New phase III trial investigates etripamil for termination of spontaneous PSVT

TAS-114 combined with S-1 shows preliminary efficacy in pretreated advanced gastric cancer patients

Japanese researchers present phase II data on TAS-205 in patients with DMD

Phase III maintenance trial of Ninlaro in multiple myeloma meets primary endpoint

Phase III study of Imbruvica in treatment-naive DLBCL misses primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...